Clinical Trial Update: Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) [Phase 2]

View source ↗

Summary

Phase 2 study of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma and Richter syndrome has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mediastinal Large B-cell Lymphoma
• Richter Syndrome

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Mediastinal Large B-cell Lymphoma, Richter Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2020-06-24